NCT05488548View on ClinicalTrials.gov

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic LeukemiaMyelofibrosis
Interventions
DRUG

EP31670

EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.

Trial Locations (6)

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

55905

RECRUITING

Mayo Clinic Rochester, Rochester

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

98109

RECRUITING

University of Washington/Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Epigenetix, Inc.
All Listed Sponsors
lead

Epigenetix, Inc.

INDUSTRY